



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

### Complete if Known

Application Number	10/644,143
Filing Date	Concurrently Herewith
First Named Inventor	Connie Sanchez
Art Unit	N/A
Examiner Name	Not Yet Assigned

Attorney Docket Number 05432/100J951-US4

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PK	AA	US-6,469,064 B2	10-22-2002	Druzgala	
	AB	US-6,333,357 B1	12-25-2001	Eig	
	AC	US-6,159,971	12-12-2000	Berg et al.	
	AD	US-6,147,072	11-14-2000	Bymaster et al.	
	AE	US-6,069,177	05-30-2000	Carlier et al.	
	AF	US-5,962,514	10-05-1999	Evenden et al.	
	AG	US-5,958,429	09-28-1999	Wong	
	AH	US-5,788,986	08-04-1998	Dodman	
	AI	US-5,648,396	07-15-1997	Young et al.	
	AJ	US-5,296,507	03-22-1994	Tanaka et al.	
	AK	US-5,114,976	05-19-1992	Norden	
	AL	US-4,962,128	10-09-1990	Doogen et al.	
	AM	US-4,943,590	07-24-1990	Boegesoe et al.	
	AN	US-4,902,710	02-20-1990	Foster et al.	
	AO	US-4,650,884	01-23-1979	Bogeso et al.	
	AP	US-4,136,193	01-23-1979	Bogeso et al.	
PK	AQ	US-3,467,675	09-16-1969	Peterson et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
PK	BA	WO-00/15220	03-23-2000	Astra Aktiebolag		
	BB	WO-01/54681 A2	08-02-2001	Massachusetts Institute of Technology		
	BC	WO-00/15219	03-23-2000	Astra Aktiebolag		
	BD	WO-00/03701	01-27-2000	Massachusetts Institute of Technology		
	BE	WO-00/02551	01-20-2000	NPS Pharmaceutical, Inc.		
	BF	EP-0759299	02-26-1997	Eli Lilly and Company		
	BG	EP-0714663 A2	06-05-1996	Eli Lilly and Company		
	BH	WO-93/09769	05-27-1993	Sepracor, Inc.		
	BI	WO-00/34263	06-15-2000	H Lundbeck A/S		
PK	BJ	WO-92/18005	10-29-1992	National Institutes of Health		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

(W:054 321001)	Krass, Frederick	Date Considered	7-26-04
-------------------	------------------	-----------------	---------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	10/644,143
				Filing Date	Concurrently Herewith
				First Named Inventor	Connie Sanchez
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	
05432/100J951-US4					

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
#K	CA	A.F. Joubert et al., "Citalopram and Anxiety Disorders," Rev. Contemp. Pharmacother 10: 79-131 (1999)			T <sup>2</sup>
	CB	Ulla M. Lepola et al., "A Controlled Perspective, 1-Year Trial of Citalopram in the Treatment of Panic Disorder," J. Clin. Psychiatry 59, 10: 528-534 (1998)			
	CC	H. Koponen et al., "Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study," Acta Psychiatrica Scandinavica 96:343-346 (1997)			
	CD	Dan J. Stein et al., "Use of serotonin selective reuptake inhibitor citalopram in obsessive-compulsive disorder," Journal of Serotonin Research 1: 29-33 (1996)			
	CE	Bigler, Allan et al., "Quantitative Structure-activity Relationships In a Series of Selective 5-HT uptake inhibitors," Eur. J. Med. Chem. 3:289-295 (1997)			
	CF	Soraya Seedat et al., "Open Trial of Citalopram in adults with post-traumatic stress disorder," International Journal of Neuropsychopharmacology 3: 135-140 (2000)			
	CG	Ihoko Muraki et al., "Effect of subchronic lithium carbonate treatment on anxiolytic-like effect of citalopram and MKC-242 in conditioned fear stress in the rat," European Journal of Pharmacology 383:223-229 (1999)			
	CH	Jennifer Y. Tan et al, "Citalopram in the Treatment of Depression and Other Potential Uses in Psychiatry," Pharmacotherapy 19, 6: 675-689 (1999)			
	CI	Mario Amore et al., "Short-term and Long-term evaluation of Selective Serotonin Reuptake Inhibitors in the Treatment of Panic Disorder: Fluoxetine vs. Citalopram," Hum. Psychopharmacol. Clin. Exp. 14: 435-440 (1999)			
	CJ	Emanuela Mundo, M.D. et al., "Efficacy of Fluvoxamine, Paroxetine, and Citalopram in the Treatment of Obsessive-Compulsive Disorder: A Single-Blind Study," Journal of Clinical Psychopharmacology 17, 4: 267-271 (August 1997)			
	CK	Zoltan Rihmer, "Successful treatment of salbutamol-induced panic disorder with citalopram," European Neuropsychopharmacology 7:241-242 (1997)			
	CL	Takeshi Inoue et al., "Effect of citalopram, a selective serotonin reuptake inhibitor, on the acquisition of conditioned freezing," European Journal of Pharmacology 311: 1-6 (1996)			
	CM	U. Lepola et al., "Citalopram in the Treatment of Early-onset Panic Disorder and School Phobia," Pharmacopsychiatry 29: 30-32 (January 1996)			
✓	CN	J. Hyttel et al., "The Pharmacology of Citalopram," Rev. Contemp. Pharmacother. 6: 271-285 (1995)			
#K	CO	American Psychiatric Association, "DSM-IV" (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition): 393-444 (1994)			

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

(W)1054 3210011	Kraus, Frederick	Date Considered	7-26-04
--------------------	------------------	-----------------	---------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	05432/100J951-US4
-------	---	----	---	------------------------	-------------------

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
FK	1	EP-0474580	03-11-1992	H Lundbeck A/S		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
FK	2	Hytell, J., Prog. Neuro-Psychopharmacol. & Biol. Psychiat., 1982, 6, 277-295	
FK	3	Gravem, A., Acta Psychiatr. Scand., 1987, 75, 478-486	
FK	4	Sanchez, C., Effect of serotonergic drugs on footshock-induced ultrasonic vocalization in adult male rats, Behav. Pharmacol. 1993; 4:267-277	
FK	5	Sanchez, C., Pharmacol. Toxicol. 77, 71-78 (1995)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

W:1054  
321001

Krass, Frederick

Date  
Considered

7-26-04